124I-Iodopyridopyrimidinone for PET of Abl Kinase–Expressing Tumors In Vivo-Reference-Cited by-同舟云学术

124I-Iodopyridopyrimidinone for PET of Abl Kinase–Expressing Tumors In Vivo

Published:2010-01 Issue:1 Volume:51 Page:121-129
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Doubrovin Mikhail,Kochetkova Tatiana,Santos Elmer,Veach Darren R.,Smith-Jones Peter,Pillarsetty Nagavarakishore,Balatoni Julius,Bornmann William,Gelovani Juri,Larson Steven M.

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference47 articles.

1. Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas

2. The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

3. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

4. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

5. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma;Pharmaceuticals;2021-06-29

2. Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging;Journal of Nuclear Medicine;2018-04-13

3. Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging;Molecules;2015-12-09

4. Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine;Current Pharmaceutical Design;2014-05-31

5. Effect of Small-Molecule Modification on Single-Cell Pharmacokinetics of PARP Inhibitors;Molecular Cancer Therapeutics;2014-02-19